NCT01154335 2022-05-03
Everolimus and OSI-906 for Patients With Refractory Metastatic Colorectal Cancer
SCRI Development Innovations, LLC
Phase 1 Completed
SCRI Development Innovations, LLC
Novartis
Dana-Farber Cancer Institute
University of Utah
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins